Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Core Insights - Salarius Pharmaceuticals has clarified that its common stock continues to trade on the Nasdaq under the ticker "SLRX" despite inaccuracies reported by S&P CapIQ regarding its merger with Decoy Therapeutics and claims of delisting [1][2] Financial Overview - The company completed an underwritten public offering on November 13, 2025, raising gross proceeds of $8 million, resulting in pro forma cash of approximately $14 million [2] - The combined company has approximately 5.9 million shares of common stock outstanding [2] Business Focus - Salarius is focused on advancing Decoy's pipeline of peptide conjugate therapeutics through its IMPACT platform, which utilizes AI and machine learning for drug development [4] - The company aims to address serious unmet medical needs with its drug candidates [4] Development Plans - Over the next 12 months, Decoy plans to advance its lead asset, a pan-coronavirus antiviral, towards filing an Investigational New Drug (IND) application with the FDA [3] - Additional programs include a broad-acting antiviral for flu, COVID-19, and RSV, as well as a peptide drug conjugate targeting gastrointestinal cancers [3]